Please provide your email address to receive an email when new articles are posted on . BOSTON — In PROTECTED TAVR, the largest-ever randomized trial of transcatheter aortic valve replacement, ...
Regional variations in market growth reflect differences in healthcare infrastructure and adoption rates, with North America and Asia-Pacific leading the way. Companies operating in the market ...
A series of neutral trials on anticoagulation in embolic stroke of undetermined source (ESUS) has moved the needle scientifically but left physicians with questions about secondary prevention and the ...
Please provide your email address to receive an email when new articles are posted on . Routine cerebral embolic protection did not reduce stroke in patients undergoing transcatheter aortic valve ...
A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...
Credit: Shutterstock. Asundexian is an investigational oral Factor XIa inhibitor. The Food and Drug Administration (FDA) has granted Fast Track designation to asundexian for the prevention of stroke ...
A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...
Verywell Health on MSN
Causes and risk factors of stroke you may not know
Medically reviewed by Huma Sheikh, MD Key Takeaways High blood pressure and atherosclerosis are common causes of strokes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback